New approach provides potential vaccine and treatment for Alzheimer’s

Date posted: January 26, 2022
Share
Alzeimers

A promising new approach to potentially treat Alzheimer’s disease – and also vaccinate against it – has been developed by a team of UK and German scientists.

Both the antibody-based treatment and the protein-based vaccine developed by the team reduced Alzheimer’s symptoms in mouse models of the disease.

The work is a collaboration between researchers at the University of Leicester, the University Medical Center Göttingen and the medical research charity LifeArc.

Rather than focus on the amyloid beta protein in plaques in the brain, which are commonly associated with Alzheimer’s disease, the antibody and vaccine both target a different soluble – form of the protein, that is thought to be highly toxic.

Amyloid beta protein naturally exists as highly flexible, string-like molecules in solution, which can join together to form fibres and plaques.

In Alzheimer’s disease, a high proportion of these string-like molecules become shortened or ‘truncated’, and some scientists now think that these forms are key to the development and progression of the disease.

Professor Thomas Bayer, from the University Medical Center Göttingen, said:

“In clinical trials, none of the potential treatments which dissolve amyloid plaques in the brain have shown much success in terms of reducing Alzheimer’s symptoms. Some have even shown negative side effects.

“So, we decided on a different approach. We identified an antibody in mice that would neutralise the truncated forms of soluble amyloid beta, but would not bind either to normal forms of the protein or to the plaques.”

Dr Preeti Bakrania and colleagues from LifeArc adapted this antibody so a human immune system wouldn’t recognise it as foreign and would accept it.

When the Leicester research group looked at how and where this ‘humanised’ antibody, called TAP01_04, was binding to the truncated form of amyloid beta, the team had a surprise.
They saw the amyloid beta protein was folded back on itself, in a hairpin-shaped structure.

Professor Mark Carr, from the Leicester Institute of Structural and Chemical Biology at the University of Leicester, explained:

“This structure had never been seen before in amyloid beta. However, discovering such a definite structure allowed the team to engineer this region of the protein to stabilise the hairpin shape and bind to the antibody in the same way. Our idea was that this engineered form of amyloid beta could potentially be used as a vaccine, to trigger someone’s immune system to make TAP01_04 type antibodies.”

When the team tested the engineered amyloid beta protein in mice, they found that mice who received this ‘vaccine’ did produce TAP01 type antibodies.

The Göttingen group then tested both the ‘humanised’ antibody and the engineered amyloid beta vaccine, called TAPAS, in two different mouse models of Alzheimer’s disease.

Based on similar imaging techniques to those used to diagnose Alzheimer’s in humans, they found that both the antibody and the vaccine helped to restore neuron function, increase glucose metabolism in the brain, restore memory loss and – even though they weren’t directly targeted – reduce amyloid beta plaque formation.

LifeArc’s Dr Bakrania said:

‘’The TAP01_04 humanised antibody and the TAPAS vaccine are very different to previous antibodies or vaccines for Alzheimer’s disease that have been tested in clinical trials, because they target a different form of the protein. This makes them really promising as a potential treatment for the disease either as a therapeutic antibody or a vaccine.

“The results so far are very exciting and testament to the scientific expertise of the team. If the treatment does prove successful, it could transform the lives of many patients.”

The researchers are now looking to find a commercial partner to take the therapeutic antibody and the vaccine through clinical trials.

For the latest from our region, subscribe to Midlands Matters, the official newsletter of the Midlands Engine.

Share

Keep Updated

Latest News & Events

Gigapark news

Economic Opportunities

Jan 16 2025

Multi-million-pound funding package to create thousands of jobs at Coventry and Warwick Gigapark
Read more
CV5_3050

Green Growth

Feb 3 2025

Blog: How the Midlands can power the UK’s clean energy revolution

Energy security has never been more urgent. In recent years, the UK has seen escalating challenges, from global geopolitical crises to rising energy prices. It is the Midlands, home to innovative industries and a strong manufacturing base, that is playing a major role in tackling these issues with the recent launch of the Midlands Engine Energy Security White Paper.  

Read more
Clusters in the Midlands

Economic Opportunities

Feb 4 2025

Clusters blog: Looking back on a month of diving into some of the biggest growth opportunities in the Midlands

Since December last year and throughout January, the Midlands Engine Partnership has led a series of Cluster deep dives - exploring the investment potential of some of the biggest clusters in our region - from aerospace to health technology.

Read more

Subscribe to our partnership newsletter